Anavex Life Sciences Corp (AVXL)

Etorro trading 970x250
Anavex Life Sciences Corp (AVXL) Logo

About Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson’s disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company’s drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials to treat Alzheimer’s and Parkinson’s diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York. Address: 51 West 52nd Street, New York, NY, United States, 10019

Anavex Life Sciences Corp News and around…

Latest news about Anavex Life Sciences Corp (AVXL) common stock and company :

2 Biotech Stocks Set to Go Supernova Soon
18 Oct, 2021 FinancialContent

Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

Anavex Life Sciences to Present at the Dawson James Securities 6th Annual Conference
15 Oct, 2021 Yahoo! Finance

NEW YORK, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will present at

Anavex Life Sciences Reports Data Review by the Independent Data Safety Monitoring Board for its Phase 2b/3 Clinical Trial of ANAVEX®2-73 in Patients with Alzheimer’s Disease
13 Oct, 2021 Yahoo! Finance

The Company anticipates topline data in the second half of 2022NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that the Independent Data Safety Moni

We Did The Math OMFS Can Go To $49
07 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco Russell 2000—Dynamic Multifactor ETF (OMFS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $48.97 per unit.

First Week of November 19th Options Trading For Anavex Life Sciences (AVXL)
05 Oct, 2021 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options become available this week, for the November 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new November 19th contracts and identified one put and one call contract of particular interest.

Anavex Life Sciences Announces Participation at 5th Pharma Pricing, Reimbursement & Market Access 2021
27 Sep, 2021 FinancialContent
Anavex Life Sciences Announces Uplisting to the NASDAQ Global Select Market®
27 Sep, 2021 FinancialContent
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
23 Sep, 2021 FinancialContent

Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ:WMG) from Equal-Weight to Overweight. ...

Anavex Life Sciences to Present at the 2021 Cantor Virtual Global Healthcare Conference
20 Sep, 2021 FinancialContent
Anavex Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
09 Sep, 2021 FinancialContent
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Autism)
26 Aug, 2021 FinancialContent
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FXS (Autism)
25 Aug, 2021 FinancialContent
11 Biotech Stocks Popular On Reddit
19 Aug, 2021 Yahoo! Finance

In this article, we discuss the 11 biotech stocks popular on Reddit. If you want to skip our detailed analysis of these stocks, go directly to the 5 Biotech Stocks Popular On Reddit. Biotechnology is one of the fields in which Reddit investors take active interest amid an explosive growth potential of the biotech industry. According […]

Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
13 Aug, 2021 FinancialContent

It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.

Anavex Life Sciences (AVXL) Q3 2021 Earnings Call Transcript
13 Aug, 2021 FinancialContent

AVXL earnings call for the period ending June 30, 2021.

October 1st Options Now Available For Anavex Life Sciences (AVXL)
12 Aug, 2021 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options begin trading today, for the October 1st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new October 1st contracts and identified one put and one call contract of particular interest.

Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Results
12 Aug, 2021 FinancialContent
Use Weakness in these 3 Alzheimer’s Disease Stocks as Opportunity
10 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Millions of Americans are struggling with Alzheimer’s, according to the Alzheimer’s Association. The disease often has a slow progression, lasting years or even decades, and it’s one of the leading causes of death in the United States. Memory loss and declines in the ability to think clearly, solve problems, and even communicate are a terrible part.... The post Use Weakness in these 3 Alzheimer’s Disease Stocks as Opportunity appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

First Week of September 24th Options Trading For Anavex Life Sciences (AVXL)
09 Aug, 2021 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options begin trading this week, for the September 24th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new September 24th contracts and identified one put and one call contract of particular interest.

What to Do After Cassava Sciences Dropped Off a Cliff
09 Aug, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cassava Sciences posted positive clinical data but triggered a sell on the news event, as SAVA stock short sellers welcomed the drop. The post What to Do After Cassava Sciences Dropped Off a Cliff appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America’s #1 EV Stock Still Flying Under the Radar

Look Under The Hood: PBSM Has 16% Upside
06 Aug, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.00 per unit.

Anavex Life Sciences to Announce Fiscal 2021 Third Quarter Financial Results on Thursday, August 12, 2021
05 Aug, 2021 FinancialContent

Webcast and Conference Call To be Held Thursday, August 12, 2021, 4:30 pm EDT

XBI, TBIO, AVXL, CYTK: Large Outflows Detected at ETF
04 Aug, 2021 FinancialContent

Symbols mentioned in this story: XBI, TBIO, AVXL, CYTK Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand..

Anavex Life Sciences to Participate in the BTIG Virtual Biotechnology Conference 2021
04 Aug, 2021 FinancialContent
First Week of AVXL September 10th Options Trading
30 Jul, 2021 FinancialContent

Investors in Anavex Life Sciences Corp (AVXL) saw new options begin trading this week, for the September 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AVXL options chain for the new September 10th contracts and identified one put and one call contract of particular interest.

70 Biggest Movers From Yesterday
30 Jul, 2021 FinancialContent

Gainers Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares surged 65.1% to settle at $5.30 on Thursday. Xenetic Biosciences recently ...

Here's Why Annovis Bio, Anavex Life Sciences, and Cassava Sciences Sank on Thursday
29 Jul, 2021 FinancialContent

A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.

12 Health Care Stocks Moving In Thursday's Intraday Session
29 Jul, 2021 FinancialContent

Gainers NanoVibronix (NASDAQ:NAOV) shares moved upwards by 38.21% to $2.64 during Thursday's regular session. Trading volume for ...

Anavex Life's Stock Declines Despite Data Shows Alzheimer's Candidate Prevent Abeta-Induced Cognitive Decline In Animal Study
29 Jul, 2021 FinancialContent

Anavex Life Sciences Corp(NASDAQ: AVXL)has reported new preclinical datafor its Alzheimer's candidate, ANAVEX2-73 ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session
29 Jul, 2021 FinancialContent

Gainers Cocrystal Pharma (NASDAQ:COCP) stock moved upwards by 30.9% to $1.44 during Thursday's pre-market session. ...

Anavex Life Sciences Corp (AVXL) is a NASDAQ Common Stock listed in , ,

970x250